Digital Therapeutics for Alzheimer's and Parkinson's Diseases: Current Trends and Future Perspectives.

IF 11.6 1区医学 Q1 CHEMISTRY, MEDICINAL

Medicinal Research Reviews Pub Date : 2025-07-31 DOI:10.1002/med.70005

Yoo Joo Jeong, Hyun-Ju Lee, Jun-Su Kim, Seung-Jae Kim, Unhui Jo, Jin Yeop Park, Su Jin Jun, Won Seok Lee, Mingoo Song, Donggii Kim, Gyoujin Cho, Jeong-Heon Song, Hyang-Sook Hoe

{"title":"Digital Therapeutics for Alzheimer's and Parkinson's Diseases: Current Trends and Future Perspectives.","authors":"Yoo Joo Jeong, Hyun-Ju Lee, Jun-Su Kim, Seung-Jae Kim, Unhui Jo, Jin Yeop Park, Su Jin Jun, Won Seok Lee, Mingoo Song, Donggii Kim, Gyoujin Cho, Jeong-Heon Song, Hyang-Sook Hoe","doi":"10.1002/med.70005","DOIUrl":null,"url":null,"abstract":"<p><p>Alzheimer's disease (AD) and Parkinson's disease (PD), which are characterized by the accumulation of misfolded protein aggregates and cognitive/motor dysfunction, are the most prevalent neurodegenerative diseases (NDDs). Despite strategic investigations aimed at augmenting the pharmaceutical pipeline, available drugs for AD and PD merely slow disease progression without curing or treating the underlying pathology. Recent technological advances have given rise to digital therapeutics (DTx): software systems that aim to prevent, cure, and manage specific diseases, including NDDs. For AD and PD, the majority of DTx focus on enhancing cognitive/executive function and motor-related functions, respectively. In this review, we describe the status of therapeutic development for AD and PD, as well as the characteristics and status of DTx targeting these NDDs. In addition, we address the limitations and challenges of DTx and their implications for the treatment of AD and PD. Ultimately, this review provides insights into the potential of DTx as a therapeutic modality and future directions for the development of DTx targeting AD and PD.</p>","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":" ","pages":""},"PeriodicalIF":11.6000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicinal Research Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/med.70005","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Alzheimer's disease (AD) and Parkinson's disease (PD), which are characterized by the accumulation of misfolded protein aggregates and cognitive/motor dysfunction, are the most prevalent neurodegenerative diseases (NDDs). Despite strategic investigations aimed at augmenting the pharmaceutical pipeline, available drugs for AD and PD merely slow disease progression without curing or treating the underlying pathology. Recent technological advances have given rise to digital therapeutics (DTx): software systems that aim to prevent, cure, and manage specific diseases, including NDDs. For AD and PD, the majority of DTx focus on enhancing cognitive/executive function and motor-related functions, respectively. In this review, we describe the status of therapeutic development for AD and PD, as well as the characteristics and status of DTx targeting these NDDs. In addition, we address the limitations and challenges of DTx and their implications for the treatment of AD and PD. Ultimately, this review provides insights into the potential of DTx as a therapeutic modality and future directions for the development of DTx targeting AD and PD.

查看原文本刊更多论文

阿尔茨海默病和帕金森病的数字治疗：当前趋势和未来前景。

阿尔茨海默病（AD）和帕金森病（PD）是最常见的神经退行性疾病（ndd），其特征是错误折叠蛋白聚集体的积累和认知/运动功能障碍。尽管战略研究旨在增加药物管道，但现有的阿尔茨海默病和帕金森病药物仅能减缓疾病进展，而不能治愈或治疗潜在病理。最近的技术进步催生了数字疗法（DTx）：旨在预防、治疗和管理特定疾病（包括ndd）的软件系统。对于AD和PD， DTx主要侧重于增强认知/执行功能和运动相关功能。在这篇综述中，我们介绍了AD和PD的治疗进展，以及针对这些ndd的DTx的特点和现状。此外，我们还讨论了DTx的局限性和挑战，以及它们对治疗AD和PD的影响。最后，本文综述了DTx作为一种治疗方式的潜力，以及DTx靶向AD和PD的未来发展方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medicinal Research Reviews 医学-药学

CiteScore

29.30

自引率

0.00%

发文量

审稿时长

2 months

期刊介绍： Medicinal Research Reviews is dedicated to publishing timely and critical reviews, as well as opinion-based articles, covering a broad spectrum of topics related to medicinal research. These contributions are authored by individuals who have made significant advancements in the field. Encompassing a wide range of subjects, suitable topics include, but are not limited to, the underlying pathophysiology of crucial diseases and disease vectors, therapeutic approaches for diverse medical conditions, properties of molecular targets for therapeutic agents, innovative methodologies facilitating therapy discovery, genomics and proteomics, structure-activity correlations of drug series, development of new imaging and diagnostic tools, drug metabolism, drug delivery, and comprehensive examinations of the chemical, pharmacological, pharmacokinetic, pharmacodynamic, and clinical characteristics of significant drugs.